STOCK TITAN

Pharvaris NV - PHVS STOCK NEWS

Welcome to our dedicated news page for Pharvaris NV (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharvaris NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharvaris NV's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.32%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
management
Pharvaris NV

Nasdaq:PHVS

PHVS Rankings

PHVS Stock Data

1.24B
16.76M
6.25%
85.94%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Leiden

About PHVS

pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.